PeptidePeptideProapoptotic targeting peptideExperimental anti-obesity

Adipotide

Also known as FTPP · Prohibitin-targeting peptide · CKGGRAKDC-GG-D(KLAKLAK)2

Written by enwyReviewed 15 Jul 20261 sources0 comments

Adipotide (FTPP) is an experimental proapoptotic peptide designed to destroy the blood supply of white fat tissue, causing fat loss. It produced weight loss in obese primates in preclinical work but also caused dose-dependent kidney toxicity. It has never been tested in a completed human efficacy trial and is not a safe or characterised human agent.

01 Overview

Adipotide is a targeting peptide fused to a proapoptotic sequence: one part homes to a marker (prohibitin) on the vasculature feeding white adipose tissue, and the other triggers apoptosis in those endothelial cells, effectively starving fat tissue of its blood supply. In obese rhesus monkeys it produced rapid, substantial weight and fat loss.

The same primate studies revealed dose-dependent renal toxicity, including changes in kidney tissue, which is a major barrier to human use. There is no completed human efficacy trial demonstrating safe weight loss, and its appearance as a research-chemical fat-loss peptide markets a compound whose best-documented finding in primates is organ toxicity.

02 Mechanism

A fusion peptide that binds prohibitin on white-adipose-tissue vasculature and delivers a proapoptotic (KLAKLAK) motif, inducing apoptosis of the fat-feeding endothelium so adipose tissue regresses.

03 Dosing

Tier	Dose	Route	Notes
Experimental (no validated dose)	1–5 mg/day	SubQ	No validated human dose. Primate studies used weight-based dosing associated with renal toxicity; any self-dosing is high-risk.

04 Effects

Effect	Magnitude	Evidence
Fat loss / weight lossRapid weight and fat reduction shown in obese rhesus monkeys; not demonstrated safely in humans.	Marked in obese primates	Preclinical
Reduced food intakeDecreased food intake accompanied fat loss in primate studies.	Observed in animals	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Nephrotoxicity (kidney damage)Dose-dependent kidney injury observed in primate studies, the principal barrier to human development.	Severe	Dose-dependent in primates	Preclinical
Unknown systemic apoptotic off-target effectsA proapoptotic agent may affect tissues beyond fat vasculature; unstudied in humans.	Severe	Uncharacterised	Unconfirmed

06 Legal status

United States

Investigational; not approved

Never approved; no completed human efficacy trial. Sold illicitly as a research chemical. · as of Jan 2026

07 References

Reversal of obesity by targeted ablation of adipose tissue vasculature (adipotide) in primatesScience Translational Medicine, 2011

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.